Cross-sectional and longitudinal associations between statin use and bone density: the Manitoba BMD registry
Authors' conclusion
In summary, this large observational analysis, which included both cross-sectional and longitudinal components, failed to detect a clinically meaningful benefit of statin exposure on bone density, even when taken with high adherence over several years.
Study context
- Population
- Individuals aged 40 yr and older with initial (Visit 1) and repeat (Visit 2) total hip BMD measurement by DXA within 1–10 yr, Manitoba BMD Program (February 28, 1999 to March 29, 2018)
- Participants
- 22,393 individuals
- Exposure
- Statin use vs no statin use
- Outcome
- Initial total hip BMD and annualized change in total hip BMD
Methodological detailsobservational, Manitoba BMD Program registry, linked medication records
- Observational
- Manitoba BMD Program registry
- Linked medication records
Main finding
As reported in the abstract
- Inconsistent and largely negative evidence for prior statin use affecting initial total hip BMD or BMD change during follow-up
- Greatest exposure (mean 5.1 yr prior statin use, high adherence): no clinically significant differences in covariate-adjusted initial total hip BMD or annualized change
Observational data: associations, not effects.
Further findings
- Statin users at Visit 1
- 4119 (18.3%)
- Statin users at Visit 2
- 6667 (29.8%)
Original publication
Cross-sectional and longitudinal associations between statin use and bone density: the Manitoba BMD registry. J Bone Miner Res. Published 29 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →